Cargando…

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer

The prostate‐specific membrane antigen (PSMA) has been demonstrated in numerous studies to be expressed specifically on prostate carcinoma cells and on the neovasculature of several other cancer entities. However, the simultaneous expression of PSMA on both, tumor cells as well as tumor vessels rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zekri, Latifa, Vogt, Fabian, Osburg, Lukas, Müller, Stefanie, Kauer, Joseph, Manz, Timo, Pflügler, Martin, Maurer, Andreas, Heitmann, Jonas S, Hagelstein, Ilona, Märklin, Melanie, Hörner, Sebastian, Todenhöfer, Tilmann, Calaminus, Carsten, Stenzl, Arnulf, Pichler, Bernd, la Fougère, Christian, Schneider, Marc A, Rammensee, Hans‐Georg, Zender, Lars, Sipos, Bence, Salih, Helmut R, Jung, Gundram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863392/ https://www.ncbi.nlm.nih.gov/pubmed/33372710 http://dx.doi.org/10.15252/emmm.201911902

Ejemplares similares

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
por: Kauer, Joseph, et al.
Publicado: (2021)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
por: Hörner, Sebastian, et al.
Publicado: (2022)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
por: Märklin, Melanie, et al.
Publicado: (2019)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
por: Zekri, Latifa, et al.
Publicado: (2023)

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
por: Schmied, Bastian J., et al.
Publicado: (2019)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
por: Marconato, Maddalena, et al.
Publicado: (2022)

Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging
por: Hu, Kongzhen, et al.
Publicado: (2022)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
por: Riegg, Fabian, et al.
Publicado: (2021)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer
por: Harland, Niklas, et al.
Publicado: (2021)

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
por: Schmied, Bastian J., et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
por: Lee, Sung Chang, et al.
Publicado: (2021)

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review
por: Walz, Simon, et al.
Publicado: (2020)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

Value of (18)F-PSMA-PET/MRI for Assessment of Recurring Ranula
por: Tilsen, Felix, et al.
Publicado: (2021)

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

Synthesis and Preclinical Evaluation of Three Novel (68)Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging
por: Verena, Arsyangela, et al.
Publicado: (2023)

Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies
por: Hinterleitner, Martina, et al.
Publicado: (2021)

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
por: Märklin, Melanie, et al.
Publicado: (2020)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Cost Effective Laparoendoscopic Single-Site Surgery with a Reusable Platform
por: Schwentner, C., et al.
Publicado: (2013)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity()
por: Rothfelder, Kathrin, et al.
Publicado: (2018)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB
por: Todenhöfer, Tilman, et al.
Publicado: (2021)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mp19k7deba7iridb8u8aijvplr